Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

Sermorelin vs Tesamorelin

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

Sermorelin: CTesamorelin: A
AttributeSermorelinTesamorelin
CategoryGrowth Hormone SecretagogueGrowth Hormone Secretagogue
Evidence RatingC — Phase I–II Clinical TrialsA — FDA Approved
Clinical StatusPreviously FDA-approved (Geref, discontinued); now used off-label via compoundingFDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy
MechanismSermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. The released HGH increases protein synthesis, fat breakdown (lipolysis), and tissue repair across multip...Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu...
Half-Life~10–20 minutes~26–38 minutes
Bioavailability——
Molecular Weight~3357.9 g/mol~5135.9 g/mol
WADA StatusProhibitedProhibited
Research Half-Life~10–20 minutes~26–38 minutes
Key Use Cases
  • Anti-Aging
  • Body Composition
  • Sleep
  • Body Composition
Safety Concerns
  • Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile
  • Common: injection site reactions (redness, swelling, mild pain — typically resolve within days)
  • Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
  • Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%)
  • Headache, nausea, and flu-like symptoms reported
  • May increase blood glucose -- monitoring recommended in diabetics
Contraindications
  • Active malignancy or active cancer (GH promotes cell proliferation)
  • Pregnancy and breastfeeding
  • Pituitary disorders or prior pituitary surgery
  • Uncontrolled diabetes, severe sleep apnea, or untreated hypertension
  • Pregnancy (Category X -- absolute contraindication)
  • Active cancer or history of any tumor (benign or malignant)
  • Pituitary gland disorder, tumor, or history of pituitary surgery
  • History of head injury or radiation treatment to the head
Regulatory (US)Previously FDA-approved (Geref) for pediatric GH deficiency; voluntarily discontinued by manufacturer for commercial reasons. FDA confirmed in 2013 it was not withdrawn for safety. Available via compounding pharmacies. WADA-banned.FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationSermorelinTesamorelin
Purity Standard≥98%≥98%
CAS Number86168-78-7218949-48-5
Molecular FormulaC₁₄₉H₂₄₆N₄₄O₄₂SC₂₂₃H₃₇₀N₇₂O₆₉S
Available Formats5mg10mg
Batch COAs Published1 on file1 on file
Stock StatusIn stockIn stock

Availability at Volta Peptides

Sermorelin 5mg

≥98% purity · HPLC verified · In stock

$34

Tesamorelin 10mg

≥98% purity · HPLC verified · In stock

$64

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.